<DOC>
	<DOCNO>NCT00004054</DOCNO>
	<brief_summary>RATIONALE : Hormones stimulate production prostate cancer cell . Hormone therapy may fight prostate cancer reduce production androgen . Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether hormone therapy plus radiation therapy effective without combination chemotherapy prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness hormone therapy plus radiation therapy without combination chemotherapy treat patient prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Plus Radiation Therapy With Without Combination Chemotherapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy androgen suppression radiotherapy without subsequent paclitaxel , estramustine , etoposide , term overall disease-free survival , biochemical local control , freedom distant metastasis , patient localize high-risk prostate cancer . - Compare toxic effect regimens patient . OUTLINE : This randomize study . Patients stratify accord prostate-specific antigen level ( â‰¤ 10 ng/mL vs 11-100 ng/mL ) , tumor stage ( T1-2 v T3-4 ) , Gleason score ( 7 vs 8-10 ) , prior hormone use ( yes v ) . Patients randomize one two treatment arm . All patient receive androgen suppression comprise luteinizing hormone-releasing hormone ( LHRH ) agonist AND bicalutamide OR flutamide 4 month . Beginning 8 week initiation androgen suppression , patient undergo radiotherapy daily , 5 day week , 7-8 week . Patients receive prior androgen suppression therapy count time radiotherapy start date prior hormonal therapy . - Arm I : Patients continue androgen suppression therapy ( LHRH agonist ) approximately 20 month radiotherapy complete . - Arm II : Patients continue therapy arm I receive chemotherapy begin 28 day complete radiotherapy . Chemotherapy comprise oral estramustine 3 time daily oral etoposide twice daily day 1-14 paclitaxel IV 1 hour day 2 . Chemotherapy repeat every 21 day 4 course . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 1,440 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven prostate cancer high risk relapse determine either follow : Prostatespecific antigen ( PSA ) 20100 ng/mL Gleason score least 7 ( T stage ) Clinical stage least T2 , Gleason score least 8 , PSA great 100 ng/mL Negative lymph nod No metastatic disease PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Zubrod 0 1 Life expectancy : Not specify Hematopoietic : White blood cell ( WBC ) count least 3,000/mm^3 Platelet count least 130,000/mm^3 Hemoglobin least 11.4 g/dL Hepatic : Aspartate aminotransferase ( AST ) great 2 time upper limit normal Renal : Creatinine great 2.5 mg/dL Other : No invasive cancer within past 5 year except superficial nonmelanomatous skin cancer No major medical psychiatric illness would preclude study participation Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 5 year since prior chemotherapy Endocrine therapy : At least 60 day since prior finasteride prostatic hypertrophy At least 90 day since prior testosterone No 30 day since initiation prior pharmacologic androgen ablation prostate cancer Radiotherapy : No prior pelvic radiotherapy No concurrent intensitymodulated radiotherapy Surgery : No prior radical prostatectomy No prior cryosurgery prostate cancer No prior orchiectomy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>